Patheon to Showcase API Development Capabilities at InformEx - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Patheon to Showcase API Development Capabilities at InformEx



Patheon, a provider of contract development and commercial manufacturing services, will showcase its late-stage API development capabilities at InformEx in Miami, Fla., January 21-24, 2014. In addition, many Patheon executives as well as technical and scientific professionals will also attend InformEx and will be available to discuss Patheon's API development capabilities. Patheon will be exhibiting at Booth #1010 for the duration of the conference. InformEx offers participants a direct view of what is happening globally across the fine, specialty, and custom chemical marketplace. The event brings together an international mix of buyers and sellers for four days of sourcing, education, and networking.

Source: Patheon

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here